EP2385047B1 - Piperidinyl-substituted isoquinolone derivatives - Google Patents

Piperidinyl-substituted isoquinolone derivatives Download PDF

Info

Publication number
EP2385047B1
EP2385047B1 EP11176273.8A EP11176273A EP2385047B1 EP 2385047 B1 EP2385047 B1 EP 2385047B1 EP 11176273 A EP11176273 A EP 11176273A EP 2385047 B1 EP2385047 B1 EP 2385047B1
Authority
EP
European Patent Office
Prior art keywords
alkyl
alkylene
aryl
heterocyclyl
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP11176273.8A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP2385047A1 (en
Inventor
Oliver Plettenburg
Armin Hofmeister
Dieter Kadereit
Joachim Brendel
Matthias Loehn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Priority to EP11176273.8A priority Critical patent/EP2385047B1/en
Publication of EP2385047A1 publication Critical patent/EP2385047A1/en
Application granted granted Critical
Publication of EP2385047B1 publication Critical patent/EP2385047B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Definitions

  • the present invention relates to novel isoquinolone and isoquinoline derivatives as described in the claims, their preparation and their use in the treatment and/or prevention of diseases related to the inhibition of Rho-kinase and/or of Rho-kinase mediated phosphorylation of myosin light chain phosphatase.
  • Rho-kinase 2 Activation of a small GTPase RhoA upon agonist stimulation results in conversion of RhoA from the inactive GDP-bound form to the active GTP-bound form with a subsequent binding to and activation of Rho-kinase.
  • Rho-kinase 1 and Rho-kinase 2 Two isoforms, Rho-kinase 1 and Rho-kinase 2, are known.
  • Rho-kinase 2 is expressed in vascular smooth muscle cells and endothelial cells.
  • Rho-kinase 2 Activation of Rho-kinase 2 by the active GTP-bound RhoA leads to calcium sensitization of smooth muscle cells through phosphorylation-mediated inhibition of the myosin light chain phosphatase activity and thereby up-regulation of the activity of myosin regulatory light chain ( Uehata et al., Nature 1997, 389, 990-994 ).
  • Rho-kinase is involved in vasoconstriction, including the development of myogenic tone and smooth muscle hypercontractility ( Gokina et al. J. Appl. Physiol. 2005, 98, 1940-8 ), bronchial smooth muscle contraction ( Yoshii et al. Am. J. Resp. Cell Mol. Biol. 20, 1190-1200 ), asthma ( Setoguchi et al. Br J Pharmacol. 2001, 132,111-8 ; Nakahara, et al. Eur J 2000,389,103 ) and chronic obstructive pulmonary disease (COPD, Maruoka, Nippon Rinsho, 1999, 57, 1982-7 ), hypertension, pulmonary hypertension ( Fukumoto et al.
  • nephropathy including hypertension-induced, non-hypertension-induced, and diabetic nephropathies, renal failure and peripheral occlusive arterial disease (PAOD) ( Wakino et al. Drug News Perspect. 2005, 18, 639-43 ), myocardial infarction ( Demiryurek et al. Eur J Pharmacol. 2005, 527, 129-40 , Hattori et al. Circulation, 2004, 109,2234-9 ), cardiac hypertrophy and failure ( Yamakawa, et al. Hypertension 2000, 35, 313-318 , Liao et al. Am J Physiol Cell Physiol.
  • sexual dysfunction e.g., penile erectile dysfunction ( Chitaley et al. Nature Medicine 2001, 7, 119-122 ), retinopathy, inflammation, immune diseases, AIDS, osteoporosis, endocrine dysfunctions, e.g. hyperaldosteronism, central nervous system disorders such as neuronal degeneration and spinal cord injury ( Hara, et al. JNeurosurg 2000, 93, 94 ), cerebral ischemia ( Uehata, et al. Nature 1997,389,990 ; Satoh et al. Life Sci. 2001, 69, 1441-53 ; Hitomi, et al.
  • a compound having inhibitory effect on Rho-kinase and/or on Rho-kinase mediated phosphorylation of myosin light chain phosphatase is useful for the treatment and/or prevention of cardiovascular and non-cardiovascular diseases involving Rho-kinase as the primary or secondary disease cause, like hypertension, pulmonary hypertension, ocular hypertension, retinopathy, and glaucoma, peripheral circulatory disorder, peripheral occlusive arterial disease (PAOD), coronary heart disease, angina pectoris, heart hypertrophy, heart failure, ischemic diseases, ischemic organ failure (end organ damage), fibroid lung, fibroid liver, liver failure, nephropathy, including hypertension-induced, non-hypertension-induced, and diabetic nephropathies, renal failure, fibroid kidney, renal glomerulosclerosis, organ hypertrophy, asthma, chronic obstructive pulmonary disease (COPD), adult respiratory distress syndrome, thrombotic disorders, stroke, cerebral va
  • neuropathic pain neuronal degeneration, spinal cord injury, Alzheimer's disease, premature birth, erectile dysfunction, endocrine dysfunctions, arteriosclerosis, prostatic hypertrophy, diabetes and complications of diabetes, metabolic syndrome, blood vessel restenosis, atherosclerosis, inflammation, autoimmune diseases, AIDS, osteopathy such as osteoporosis, infection of digestive tracts with bacteria, sepsis, cancer development and progression, e.g. cancers of the breast, colon, prostate, ovaries, brain and lung and their metastases.
  • WO 01/64238 describes isoquinoline-5-sulfonamide derivatives optionally substituted by a -(CH 2 ) 1-6 -O-(CH 2 ) 0-6 -, a -(CH 2 ) 0-6 -S-(CH 2 ) 0-6 - or a -(CH 2 ) 0-6 -linked heterocyclic group useful as neuroprotective agents.
  • WO 2004/106325 (Schering AG) describes prodrugs of the Rho-kinase inhibitor fasudil carrying an ether or ester group in the 1-position of the isoquinoline ring.
  • WO 2001/039726 generically describes -O-(C 0 -C 10 )alkyl-heteroaryl substituted cyclohexyl derivatives useful for the treatment of microbial infections.
  • JP 10087629 A describes isoquinoline derivatives useful for the treatment of diseases caused by Heliobacter pylori such as for example gastritis cancer or ulcer.
  • the isoquinoline derivatives may be substituted by OH in the 1-position and are preferably 5-substituted by X-[(C 1 -C 6 )alkylene)] 0-1 -Y wherein X may be oxygen and Y may be an aryl or a heterocyclic group.
  • US 5,480,883 generically discloses as EGF and/or PDGF receptor inhibitors useful for inhibiting cell proliferation compounds of the formula "Ar I - X - Ar II" wherein X may be (CHR 1 ) m -Z-(CHR 1 ) n , e.g. Z-CH 2 , wherein Z may be O, R 1 is hydrogen or alkyl, Ar I may be among others an optionally substituted isoquinolone and Ar II may be among others an optionally substituted C 3-7 monocyclic saturated heterocyclic system.
  • WO 2005/030791 (Merck & Co.) generically describes as potassium channel inhibitors for the treatment of cardiac arrhythmias, stroke, congestive heart failure etc. isoquinolone derivatives which are optionally substituted in 6-position by a group (CR e R f ) p OR 43 wherein p may be zero, and R 43 is e.g. a group R 81 defined as a 4-6 membered unsaturated or saturated monocyclic heterocylic ring with 1, 2, 3 or 4 heteroatoms selected from N, O or S; and are substituted by a directly bound optionally substituted aryl or heteroaryl ring in the 4-position.
  • WO 2005/030130 (Merck & Co.) generically describes as potassium channel inhibitors for the treatment of cardiac arrhythmias, stroke, congestive heart failure etc. isoquinoline derivatives which may be substituted by hydroxyl in the 1-position and are optionally substituted in 6-position by a group (CR e R f ) p OR 43 wherein p may be zero, and R 43 is e.g. a group R 81 defined as a 4-6 membered unsaturated or saturated monocyclic heterocylic ring with 1, 2, 3 or 4 heteroatoms selected from N, O or S; and are substituted by a directly bound optionally substituted aryl or heteroaryl ring in the 4-position.
  • WO 03/053330 (Ube ) describes isoquinolone derivatives of the formula as Rho-kinase inhibitors.
  • EP 1541 559 A1 (Asahi Kasei ) discloses 5-substituted isoquinoline derivatives useful for inhibiting the phosphorylation of myosin regulatory light chain.
  • EP 1 403 255 A1 discloses indazole derivatives as Rho-kinase inhibitors.
  • An embodiment of the present invention is a compound of the formula (I) wherein
  • one alkyl or alkylene hydrogen atom in residues R 4 , R 5 , R 7 and R 8 can optionally be substituted by OH, F, OCH 3 , COOH, COOCH 3 , NH 2 , NHCH 3 , N(CH 3 ) 2 , CONH 2 , CONHCH 3 or CON(CH 3 ) 2 .
  • Stereoisomeric forms of the isoquinolone derivatives of the formula (I) include the corresponding tautomeric 1-hydroxy-substituted isoquinoline derivatives of the formula (I') wherein R 1 is H, (C 1 -C 6 )alkyl, (C 2 -C 6 )alkenyl, (C 2 -C 6 )alkynyl, [(C 1 -C 6 )alkylene] 0-1 -(C 3 -C 8 )cycloalkyl, [(C 1 -C 6 )alkylene] 0-1 -(C 5 -C 10 )heterocyclyl, [(C 1 -C 6 )alkylene] 0-1 -(C 6 -C 10 )aryl, C(O)-(C 1 -C 6 )alkyl, C(O)(C 2 -C 6 )alkenyl, C(O)-(C 2 -C 6 )alkynyl,
  • R 2 in the compound of the formula (I) is H, the compound is thus characterized by a compound of the formula (II)
  • R 1 in the compound of the formula (I') is H, the compound is thus characterized by a compound of the formula (II')
  • the compounds (II) and (II') are tautomeric forms of each other.
  • the compound of the formula is a tautomer of the compound with the formula
  • R 6 is (C 1 -C 6 )alkyl, R', (C 1 -C 4 )alkylene-(C 3 -C 8 )cycloalkyl, (C 1 -C 4 )alkylene-(C 5 -C 10 )heterocyclyl, (C 1 -C 4 )alkylene-C(O)-(C 5 -C 10 )heterocyclyl, (C 1 -C 4 )alkylene-C(O)-(C 6 -C 10 )aryl or (C 1 -C 6 )alkylene-(C 6 -C 10 )aryl.
  • R 6 is (C 1 -C 6 )alkyl, (C 5 -C 10 )heterocyclyl, (C 3 -C 8 )cycloalkyl, (C 1 -C 4 )alkylene-(C 3 -C 8 )cycloalkyl, (C 1 -C 4 )alkylene-(C 5 -C 10 )heterocyclyl or (C 1 -C 6 )alkylene-(C 6 -C 10 )aryl.
  • R 6 is (C 1 -C 6 )alkyl, (C 3 -C 8 )cycloalkyl, (C 1 -C 4 )alkylene-(C 3 -C 8 )cycloalkyl, (C 1 -C 4 )alkylene-(C 5 -C 10 )heterocyclyl or (C 1 -C 6 )alkylene-(C 6 -C 10 )aryl.
  • R 6 is (C 1 -C 6 )alkyl, (C 3 -C 8 )cycloalkyl, (C 1 -C 4 )alkylene-(C 3 -C 8 )cycloalkyl, (C 1 -C 4 )alkylene-(C 5 -C 10 )heterocyclyl, in which the heterocyclyl is unsubstituted or substituted by (C 1 -C 4 )alkyl, or is (C 1 -C 4 )alkylene-(C 6 -C 10 )aryl, in which the aryl is unsubstituted or substituted, preferably one to three times, by halogen, (C 1 -C 4 )alkyl especially methyl, ethyl, isopropyl or 3,3,3-trifluoromethyl, O-(C 1 -C 4 )alkyl especially methoxy, SO 2 -(C 1 -C 4 )alkyl
  • R 6 is (C 1 -C 6 )alkyl, (C 3 -C 6 )cycloalkyl or (C 1 -C 4 )alkylene-(C 3 -C 6 )cycloalkyl.
  • R 6 is (C 1 -C 6 )alkyl.
  • R 6 groups are methyl, ethyl, propyl, isopropyl, cyclopropyl, 3-methyl-butyl, butyl, s-butyl, 3,3,3-trifluoropropyl or a substituent selected from the group consisting of
  • the asterisk (*) denotes where the bond is connected to the N-atom of the piperidine.
  • R 7 and R 8 are independently of each other H, halogen, CN, (C 1 -C 6 )alkyl, O-(C 1 -C 6 )alkyl, (C 2 -C 6 )alkenyl, R' or (C 1 -C 6 )alkylene-(C 3 -C 8 )cycloalkyl.
  • R 7 and R 8 are independently of each other H, halogen, CN, (C 1 -C 4 )alkyl, O-(C 1 -C 4 )alkyl, (C 2 -C 4 )alkenyl, phenyl, (C 3 -C 6 )cycloalkyl, (C 1 -C 4 )alkylene-(C 3 -C 6 )cycloalkyl or (C 5 -C 6 )heteroaryl. Even more prefered, R 7 and R 8 are independently of each other H, halogen, (C 1 -C 4 )alkyl, O-(C 1 -C 4 )alkyl or (C 3 -C 6 )cycloalkyl.
  • R 7 is H, halogen, (C 1 -C 4 )alkyl or O-(C 1 -C 4 )alkyl and R 8 is H.
  • R 7 and R 8 are independently of each other H, halogen, (C 1 -C 4 )alkyl, O-(C 1 -C 4 )alkyl or phenyl.
  • R 7 and R 8 are H.
  • R 9 is preferably halogen or (C 1 -C 4 )alkyl. More preferred, R 9 is Cl, F, methyl or ethyl. More preferably R 9 is methyl.
  • n is 0, 1, 2 or 3. More preferred, n is 0 or 1. Most preferred, n is 0.
  • the linker group L may be bound to the piperidinyl ring in any position via a piperidinyl ring carbon atom and may thereby form the (R)- or the (S)-stereoisomer of a compound according to the invention.
  • L is attached to the 4-position of the piperidinyl ring or L is attached to the 3-position of the piperidinyl ring
  • L is attached to the 4-position of the piperidinyl ring.
  • L is O-methylene, O-ethylene or O. More preferably, L is O-methylene, O-ethylene or most preferred O attached to the 4-position of the piperidinyl ring.
  • L is O.
  • one or more or all of the groups contained in the compounds of formulae (I) or (I') can independently of each other have any of the preferred, more preferred or most preferred definitions of the groups specified above or any one or some of the specific denotations which are comprised by the definitions of the groups and specified above, all combinations of preferred definitions, more preferred or most preferred and/or specific denotations being a subject of the present invention.
  • the invention includes the compounds of the formulae (I) or (I') in all stereoisomeric forms and mixtures of stereoisomeric forms in all ratios, and/or their physiologically acceptable salts.
  • a preferred embodiment of the present invention is a compound of the formula (I), (I'), (II) or (II') wherein R 3 is H, halogen, CN, (C 1 -C 6 )alkyl, (C 1 -C 6 )alkylene-R', OH, O-R", NH 2 , or NHR"; R 4 is H, halogen, hydroxy, CN, (C 1 -C 6 )alkyl, (C 3 -C 8 )cycloalkyl, (C 1 -C 6 )alkylene-R'; R 5 is H, halogen, CN, NO 2 , (C 1 -C 6 )alkyl, (C 2 -C 6 )alkenyl, R', (C 1 -C 6 )alkylene-(C 6 -C 10 )aryl, (C 2 -C 6 )alkenylene-(C 6 -C 10 )aryl, (C 1 -C 6
  • a further preferred embodiment of the present invention is a compound of the formula (I), (I'), (II) or (II') wherein R 3 is H, halogen, CN, (C 1 -C 6 )alkyl, (C 1 -C 2 )alkylene-R' or NHR"; R 4 is H, halogen, CN, (C 1 -C 6 )alkyl, (C 3 -C 8 )cycloalkyl, (C 1 -C 2 )alkylene-R'; R 5 is H, halogen, CN, NO 2 , (C 1 -C 6 )alkyl, (C 2 -C 6 )alkenyl, R', (C 1 -C 6 )alkylene-(C 6 -C 10 )aryl, (C 2 -C 6 )alkenylene-(C 6 -C 10 )aryl, (C 1 -C 6 )alkylene-(C 5 -C 10 )
  • a most preferred embodiment of the present invention is a compound of the formula (I), (I'), (II) or (II') wherein R 3 is H, halogen, CN, (C 1 -C 6 )alkyl, (C 1 -C 2 )alkylene-R' or NHR"; R 4 is H, halogen, CN, (C 1 -C 4 )alkyl, (C 3 -C 6 )cycloalkyl, (C 1 -C 2 )alkylene-R'; R 5 is H, halogen, CN, NO 2 , (C 1 -C 6 )alkyl, (C 2 -C 6 )alkenyl, R', (C 1 -C 6 )alkylene-(C 6 -C 10 )aryl, (C 2 -C 6 )alkenylene-(C 6 -C 10 )aryl, (C 1 -C 6 )alkylene-(C 5 -C 10 )
  • R 3 is H, halogen, CN, (C 1 -C 6 )alkyl, (C 1 -C 6 )alkylene-R', OH, O-R", NH 2 , or NHR"
  • R 4 is H, halogen, hydroxy, CN, (C 1 -C 6 )alkyl, (C 3 -C 8 )cycloalkyl, (C 1 -C 6 )alkylene-R'
  • R 5 is H, halogen, CN, NO 2 , (C 1 -C 6 )alkyl, (C 2 -C 6 )alkenyl, R', (C 1 -C 6 )alkylene-(C 6 -C 10 )aryl, (C 2 -C 6 )alkenylene-(C 6 -C 10 )aryl, (C 1 -C 6 )alkenylene-(C 6 -C 10 )aryl, (C 1 -C 6
  • a further preferred embodiment of the present invention is a compound of the formula (I), (I'), (II) or (II') wherein R 3 is H, halogen, CN, (C 1 -C 6 )alkyl, or (C 1 -C 2 )alkylene-R'; R 4 is H, halogen, CN, (C 1 -C 6 )alkyl, or (C 1 -C 2 )alkylene-R'; R 5 is H, halogen, CN, NO 2 , (C 1 -C 6 )alkyl, R 6 is (C 3 -C 8 )cycloalkyl, (C 1 -C 8 )alkyl, (C 1 -C 3 )alkylene-(C 3 -C 6 )cycloalkyl, (C 1 -C 3 )alkylene-(C 6 -C 10 )aryl or (C 1 -C 3 )alkylene-(C 5 -C 10 )he
  • a most preferred embodiment of the present invention is a compound of the formula (I), (I'), (II) or (II') wherein R 3 is H; R 4 is H, halogen, or (C 1 -C 4 )alkyl; R 5 is H, halogen or (C 1 -C 6 )alkyl; R 6 is (C 3 -C 6 )cycloalkyl, (C 1 -C 4 )alkyl, (C 1 -C 2 )alkylene-(C 3 -C 6 )cycloalkyl, (C 1 -C 4 )alkylene-(C 5 -C 10 )heterocyclyl, in which heterocyclyl is unsubstituted or substituted by (C 1 -C 4 )alkyl, or is (C 1 -C 4 )alkylene-(C 6 -C 10 )aryl in which aryl is unsubstituted or substituted by halogen, (C 1 -C
  • one or more or all of the groups can have any of its preferred, more preferred, most preferred definitions specified above or any one or some of the specific denotations which are comprised by its definitions and are specified above.
  • Physiologically acceptable salts of compounds of the formulae (I) and (I') mean both their organic and inorganic salts as described in Remington's Pharmaceutical Sciences (17th edition, page 1418 (1985 )).
  • preference is given for acidic groups inter alia to sodium, potassium, calcium and ammonium salts; preference is given for basic groups inter alia to salts of maleic acid, fumaric acid, succinic acid, malic acid, tartaric acid, methylsulfonic acid, hydrochloric acid, sulfuric acid, phosphoric acid or of carboxylic acids or sulfonic acids, for example as hydrochlorides, hydrobromides, phosphates, sulfates, methanesulfonates, acetates, lactates, maleates, fumarates, malates, gluconates, and salts of amino acids, of natural bases or carboxylic acids.
  • the preparation of physiologically acceptable salts from compounds of the formulae (I) and (I') which are capable of salt formation, including their stereoisomeric forms, takes place in a manner known per se.
  • the compounds of the formula (I) form stable alkali metal, alkaline earth metal or optionally substituted ammonium salts with basic reagents such as hydroxides, carbonates, bicarbonates, alcoholates and ammonia or organic bases, for example trimethyl- or triethylamine, ethanolamine, diethanolamine or triethanolamine, trometamol or else basic amino acids, for example lysine, ornithine or arginine.
  • basic reagents such as hydroxides, carbonates, bicarbonates, alcoholates and ammonia or organic bases, for example trimethyl- or triethylamine, ethanolamine, diethanolamine or triethanolamine, trometamol or else basic amino acids, for example lysine, ornithine or arginine.
  • stable acid addition salts can also be
  • Suitable pharmaceutically acceptable acid addition salts of the compounds of the invention are salts of inorganic acids such as hydrochloric acid, hydrobromic, phosphoric, metaphosphoric, nitric and sulfuric acid, and of organic acids such as, for example, acetic acid, benzenesulfonic, benzoic, citric, ethanesulfonic, fumaric, gluconic, glycolic, isethionic, lactic, lactobionic, maleic, malic, methanesulfonic, succinic, p-toluenesulfonic and tartaric acid.
  • inorganic acids such as hydrochloric acid, hydrobromic, phosphoric, metaphosphoric, nitric and sulfuric acid
  • organic acids such as, for example, acetic acid, benzenesulfonic, benzoic, citric, ethanesulfonic, fumaric, gluconic, glycolic, isethionic, lactic, lactobionic, maleic
  • Salts with a physiologically unacceptable anion such as, for example, trifluoroacetate likewise belong within the framework of the invention as useful intermediates for the preparation or purification of pharmaceutically acceptable salts and/or for use in nontherapeutic, for example in vitro, applications.
  • the invention relates to a compound of the formula (I) or (I') in the form of their racemates, racemic mixtures and pure enantiomers and to their diastereomers and mixtures thereof.
  • radicals or substituents may occur more than once in the compounds of the formulae (I) or (I'), they may all, independently of one another, have the stated meaning and be identical or different.
  • the compounds of the invention may also exist in various polymorphous forms and/or solvates, for example as amorphous and crystalline polymorphous forms. All polymorphous forms of the compounds of the invention belong within the framework of the invention and are a further aspect of the invention.
  • alkyl and the corresposponding alkylene substituents are understood as a hydrocarbon residue which can be linear, i.e. straight-chain, or branched and has 1, 2, 3, 4, 5 or 6 carbon atoms, respectively, where applicable. This also applies if an alkyl group occurs as a substituent on another group, for example in an alkoxy group (O-alkyl), S-alkyl or a -O(C 1 -C 6 )alkylene-O-, an alkoxycarbonyl group or an arylalkyl group.
  • alkyl groups are methyl, ethyl, propyl, butyl, pentyl or hexyl, the n-isomers of all these groups, isopropyl, isobutyl, 1-methylbutyl, isopentyl, neopentyl, 2,2-dimethylbutyl, 2-methylpentyl, 3-methylpentyl, isohexyl, sec-butyl, tert-butyl or tert-pentyl.
  • Alkyl groups may - if not otherwise stated - be halogenated once or more, e.g. alkyl groups may be fluorinated, e.g. perfluorinated. Examples of halogenated alkyl groups are CF 3 and CH 2 CF 3 , OCF 3 , SCF 3 , or -O-(CF 2 ) 2 -O-.
  • Halogen means fluoro, chloro, bromo or iodo.
  • (C 3 -C 8 )cycloalkyl groups are cyclic alkyl groups containing 3, 4, 5, 6, 7 or 8 ring carbon atoms like cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cyclooctyl, which can also be substituted and/or contain 1 or 2 double bounds (unsaturated cycloalkyl groups) like, for example, cyclopentenyl or cyclohexenyl can be bonded via any carbon atom.
  • a (C 6 -C 10 )aryl group means an aromatic ring or a ring system which comprises two aromatic rings which are fused or otherwise linked, for example a phenyl, naphthyl, biphenyl, tetrahydronaphthyl, alpha- or beta-tetralon-, indanyl- or indan-1-on-yl group.
  • a preferred (C 6 -C 10 )aryl group is phenyl.
  • a (C 5 -C 10 )heterocyclyl group means a mono- or bicyclic ring system which comprises, apart from carbon, one or more heteroatoms such as, for example, e.g. 1, 2 or 3 nitrogen atoms, 1 or 2 oxygen atoms, 1 or 2 sulfur atoms or combinations of different hetero atoms.
  • the heterocyclyl residues can be bound at any positions, for example on the 1-position, 2-position, 3-position, 4-position, 5-position, 6-position, 7-position or 8-position.
  • Suitable (C 5 -C 10 )heterocyclyl group include acridinyl, azocinyl, benzimidazolyl, benzofuryl, benzomorpholinyl, benzothienyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, carbazolyl, 4aH-carbazolyl, carbolinyl, furanyl, quinazolinyl, quinolinyl, 4H-quinolizinyl, quinoxalinyl, quinuclidinyl, chromanyl, chromenyl, chromen-2-onyl, cinnolinyl, decahydroquinolinyl, 2H,6H-1,5,2-dithiazinyl, dihydrofuro[2,3-b]-tetrahydrofuran, fu
  • Preferred examples of (C 5 -C 10 )heterocyclyl residues are pyrazinyl, pyridyl, pyrimidinyl, pyrazolyl, morpholinyl, pyrrolidinyl, piperazinyl, piperidinyl, thienyl, benzofuryl, quinolinyl, tetrazolyl and triazolyl.
  • (C 6 -C 10 )aryl and (C 5 -C 10 )heterocyclyl groups are unsubstituted or, unless otherwise stated, substituted one or more times by suitable groups independently selected from halogen, CF 3 , NO 2 , N 3 , CN, C(O)-(C 1 -C 6 )alkyl, C(O)-( C 6 -C 10 )aryl , COOH, COO(C 1 -C 6 )alkyl, CONH 2 , CONH(C 1 -C 6 )alkyl, CON[(C 1 -C 6 )alkyl] 2 , (C 3 -C 8 )cycloalkyl, (C 1 -C 6 )alkyl, (C 1 -C 6 )alkylene-OH, (C 1 -C 6 )alkylene-NH 2 , (C 1 -C 6 )alkylene-NH(C 1 -C 6 )alkyl, (
  • substituents for (C 6 -C 10 )aryl groups are (C 1 -C 4 )alkyl, O-(C 1 -C 4 )alkyl, O-phenyl, C(O)O-(C 1 -C 6 )alkyl, C(O)OH, C(O)-(C 1 -C 4 )alkyl, halogen, NO 2 , SO 2 NH 2 , CN, SO 2 -(C 1 -C 4 )alkyl, NH-SO 2 -(C 1 -C 4 )alkyl, NH 2 , NH-C(O)-(C 1 -C 4 )alkyl, (C 3 -C 8 )cycloalkyl, (C 1 -C 4 )alkyl-OH, C(O)N[(C 1 -C 4 )alkyl] 2 , C(O)NH 2 , N[(C 1 -C 4 )alkyl]
  • substituents for (C 6 -C 10 )aryl are halogen, (C 1 -C 4 )alkyl especially methyl, ethyl, isopropyl or 3,3,3-trifluoromethyl, O-(C 1 -C 4 )alkyl especially methoxy, SO 2 -(C 1 -C 4 )alkyl especially SO 2 -CH 3 or SO 2 -CF 3 , or N[(C 1 -C 4 )alkyl] 2 especially N[(CH 3 ) 2 .
  • the substituent can be located in the 2-position, the 3-position or the 4-position, with the 3-position and the 4-position being preferred. If a phenyl group carries two substituents, they can be located in 2,3-position, 2,4-position, 2,5-position, 2,6-position, 3,4-position or 3,5-position. In phenyl groups carrying three substituents the substituents can be located in 2,3,4-position, 2,3,5-position, 2,3,6-position, 2,4,5-position, 2,4,6-position, or 3,4,5-position.
  • phenyl groups correspondingly apply to divalent groups derived from phenyl groups, i.e. phenylene which can be unsubstituted or substituted 1,2-phenylene, 1,3-phenylene or 1,4-phenylene.
  • the above statements also correspondingly apply to the aryl subgroup in arylalkylene groups.
  • arylalkylene groups which can also be unsubstituted or substituted in the aryl subgroup as well as in the alkylene subgroup, are benzyl, 1-phenylethylene, 2-phenylethylene, 3-phenylpropylene, 4-phenylbutylene, 1-methyl-3-phenyl-propylene.
  • preferred substituents for (C 5 -C 10 )heterocyclyl groups are (C 1 -C 4 )alkyl, O-(C 1 -C 4 )alkyl, (C 1 -C 4 )alkylene-phenyl, halogen, (C 1 -C 4 )alkylene-O-(C 1 -C 4 )alkyl, (C 5 -C 10 )heterocyclyl, (C 1 -C 4 )alkylene-N[(C 1 -C 4 )alkyl] 2 , or (C 6 -C 10 )aryl, wherein the (C 6 -C 10 )aryl may be further substituted by (C 1 -C 4 )alkyl, (C 1 -C 4 )alkylene-O-(C 1 -C 6 )alkyl, O-(C 1 -C 6 )alkyl-(C 6 -C 10 )aryl, or may be
  • the present invention therefore also relates to the compounds of the formulae (I) or (I'), or their physiologically acceptable salts and/or stereoisomeric forms for use as pharmaceuticals (or medicaments), to the use of the compounds of the formulae (I) or (I'), or their physiologically acceptable salts and/or stereoisomeric forms for the production of pharmaceuticals for the treatment and/or prevention of diseases associated with Rho-kinase and/or Rho-kinase mediated phosphorylation of myosin light chain phosphatase, i.e.
  • hypertension for the treatment and/or prevention of hypertension, pulmonary hypertension, ocular hypertension, retinopathy, glaucoma, peripheral circulatory disorder, peripheral occlusive arterial disease (PAOD), coronary heart disease, angina pectoris, heart hypertrophy, heart failure, ischemic diseases, ischemic organ failure (end organ damage), fibroid lung, fibroid liver, liver failure, nephropathy, including hypertension-induced, non-hypertension-induced, and diabetic nephropathies, renal failure, fibroid kidney, renal glomerulosclerosis, organ hypertrophy, asthma, chronic obstructive pulmonary disease (COPD), adult respiratory distress syndrome, thrombotic disorders, stroke, cerebral vasospasm, cerebral ischemia, pain, e.g.
  • PAOD peripheral occlusive arterial disease
  • COPD chronic obstructive pulmonary disease
  • neuropathic pain neuropathic pain
  • spinal cord injury Alzheimer's disease, premature birth, erectile dysfunction, endocrine dysfunctions, arteriosclerosis, prostatic hypertrophy, diabetes and complications of diabetes, metabolic syndrome, blood vessel restenosis, atherosclerosis, inflammation, autoimmune diseases, AIDS, osteopathy such as osteoporosis, infection of digestive tracts with bacteria, sepsis, cancer development and progression, e.g. cancers of the breast, colon, prostate, ovaries, brain and lung and their metastases.
  • the treatment and/or prevention of diseases in humans is a preferred embodiment but also warm blooded animals such as cats, dogs, rats, horses etc. may be treated with the compounds of the present invention.
  • the present invention furthermore relates to pharmaceutical preparations (or pharmaceutical compositions) which contain an effective amount of at least one compound of the formula (I) or (I'), or its physiologically acceptable salts and/or stereoisomeric forms and a pharmaceutically acceptable carrier, i. e. one or more pharmaceutically acceptable carrier substances (or vehicles) and/or additives (or excipients).
  • a pharmaceutically acceptable carrier i. e. one or more pharmaceutically acceptable carrier substances (or vehicles) and/or additives (or excipients).
  • the pharmaceuticals can be administered orally, for example in the form of pills, tablets, lacquered tablets, coated tablets, granules, hard and soft gelatin capsules, solutions, syrups, emulsions, suspensions or aerosol mixtures.
  • Administration can also be carried out rectally, for example in the form of suppositories, or parenterally, for example intravenously, intramuscularly or subcutaneously, in the form of injection solutions or infusion solutions, microcapsules, implants or rods, or percutaneously or topically, for example in the form of ointments, solutions or tinctures, or in other ways, for example in the form of aerosols or nasal sprays.
  • compositions according to the invention are prepared in a manner known per se and familiar to one skilled in the art, pharmaceutically acceptable inert inorganic and/or organic carrier substances and/or additives being used in addition to the compound(s) of the formulae (I) or (I'), or its (their) physiologically acceptable salts and/or its (their) stereoisomeric forms as well as their prodrugs.
  • pharmaceutically acceptable inert inorganic and/or organic carrier substances and/or additives being used in addition to the compound(s) of the formulae (I) or (I'), or its (their) physiologically acceptable salts and/or its (their) stereoisomeric forms as well as their prodrugs.
  • pharmaceutically acceptable inert inorganic and/or organic carrier substances and/or additives being used in addition to the compound(s) of the formulae (I) or (I'), or its (their) physiologically acceptable salts and/or its (their) stereoisomeric forms as well as their prodrugs.
  • Carrier substances for soft gelatin capsules and suppositories are, for example, fats, waxes, semisolid and liquid polyols, natural or hardened oils, etc.
  • Suitable carrier substances for the production of solutions, for example injection solutions, or of emulsions or syrups are, for example, water, saline, alcohols, glycerol, polyols, sucrose, invert sugar, glucose, vegetable oils, etc.
  • Suitable carrier substances for microcapsules, implants or rods are, for example, copolymers of glycolic acid and lactic acid.
  • the pharmaceutical preparations normally contain about 0.5 to about 90 % by weight of a compound of the formula (I) or (I'), or their physiologically acceptable salts and/or their stereoisomeric forms.
  • the amount of the active ingredient of the formula (I) or (I') and/or its physiologically acceptable salts and/or its stereoisomeric forms in the pharmaceutical preparations normally is from about 0.5 to about 1000 mg, preferably from about 1
  • the pharmaceutical preparations can contain one or more additives such as, for example, fillers, disintegrants, binders, lubricants, wetting agents, stabilizers, emulsifiers, preservatives, sweeteners, colorants, flavorings, aromatizers, thickeners, diluents, buffer substances, solvents, solubilizers, agents for achieving a depot effect, salts for altering the osmotic pressure, coating agents or antioxidants.
  • additives such as, for example, fillers, disintegrants, binders, lubricants, wetting agents, stabilizers, emulsifiers, preservatives, sweeteners, colorants, flavorings, aromatizers, thickeners, diluents, buffer substances, solvents, solubilizers, agents for achieving a depot effect, salts for altering the osmotic pressure, coating agents or antioxidants.
  • the pharmaceutical preparations can also contain two or more compounds of the formulae (I) and/or (I') and/or their physiologically acceptable salts and/or their stereoisomeric forms.
  • a pharmaceutical preparation contains two or more compounds of the formulae (I) and/or (I')
  • the selection of the individual compounds can aim at a specific overall pharmacological profile of the pharmaceutical preparation. For example, a highly potent compound with a shorter duration of action may be combined with a long-acting compound of lower potency.
  • the flexibility permitted with respect to the choice of substituents in the compounds of the formulae (I) or (I') allows a great deal of control over the biological and physico-chemical properties of the compounds and thus allows the selection of such desired compounds.
  • the pharmaceutical preparations can also contain one or more other therapeutically or prophylactically active ingredients.
  • the dose can vary within wide limits and, as is customary and is known to the physician, is to be suited to the individual conditions in each individual case. It depends, for example, on the specific compound employed, on the nature and severity of the disease to be treated, on the mode and the schedule of administration, or on whether an acute or chronic condition is treated or whether prophylaxis is carried out.
  • An appropriate dosage can be established using clinical approaches well known in the medical art.
  • the daily dose for achieving the desired results in an adult weighing about 75 kg is from about 0.01 to about 100 mg/kg, preferably from about 0.1 to about 50 mg/kg, in particular from about 0.1 to about 10 mg/kg, (in each case in mg per kg of body weight).
  • the daily dose can be divided, in particular in the case of the administration of relatively large amounts, into several, for example 2, 3 or 4, part administrations. As usual, depending on individual behavior it may be necessary to deviate upwards or downwards from the daily dose indicated.
  • the compounds of the formulae (I) or (I') can be used as synthesis intermediates for the preparation of other compounds, in particular of other pharmaceutical active ingredients, which are obtainable from the compounds of the formula I, for example by introduction of substituents or modification of functional groups.
  • protective groups that may still be present in the products obtained in the coupling reaction are then removed by standard procedures.
  • tert-butyl protecting groups in particular a tert-butoxycarbonyl group which is a protection form of an amino group
  • tert-butoxycarbonyl group which is a protection form of an amino group
  • functional groups can be generated from suitable precursor groups.
  • a conversion into a physiologically acceptable salt or a prodrug of a compound of the formulae (I) or (I') can then be carried out by known processes.
  • a reaction mixture containing a final compound of the formula (I) or (I') or an intermediate is worked up and, if desired, the product is then purified by customary processes known to those skilled in the art.
  • a synthesized compound can be purified using well known methods such as crystallization, chromatography or reverse phase-high performance liquid chromatography (RP-HPLC) or other methods of separation based, for example, on the size, charge or hydrophobicity of the compound.
  • RP-HPLC reverse phase-high performance liquid chromatography
  • well known methods such as amino acid sequence analysis, NMR, IR and mass spectrometry (MS) can be used for characterizing a compound of the invention.
  • Isoquinolinones can by synthesized via a variety of methods.
  • the following general schemes illustrate some of the possible ways to access isoquinolones, but do not limit the present invention.
  • a suitably substituted aldehyde for example substituted by X or Y being independently from each other hydrogen, alkyl, alkoxy or halogen attached in a suitable position, can be reacted with a suitable compound such as for example an acetal of aminoacetaldehyde in a solvent like THF, chloroform or toluene under acid catalysis by toluene sulfonic acid or another appropriate acid to give imine ( ii ) wherein Q' can be for instance methyl or ethyl, which in turn can be cyclized by different methods to the isoquinoline ( iii ).
  • a suitable compound such as for example an acetal of aminoacetaldehyde in a solvent like THF, chloroform or toluene under acid catalysis by toluene sulfonic acid or another appropriate acid to give imine ( ii ) wherein Q' can be for instance methyl or ethyl, which in turn can be cycl
  • this can be done by Lewis acid catalysis by suitable Lewis acids like titanium tetrachloride, ferrous halides, aluminium halides etc. at temperatures ranging from ambient to 100 °C or by reducing the imine to the corresponding amine by action of a suitable reducing agent like sodium borohydride, converting the amine into an amide or sulphonamide by reaction with a suitable acid chloride and subsequent cyclization to the isoquinoline by action of an appropriate lewis acid.
  • the isoquinoline ( iii ) itself can then be converted to the corresponding N-oxide ( iv ) by action of a suitable oxidative agent like hydrogen peroxide, m-chloro perbenzoic acid or others at room temperature or elevated temperature.
  • the N-oxide ( iv ) can then be converted into the 1-chloro-isoquinoline derivative ( v ) by reacting it with a reagent like phosphorous oxy chloride in or without presence of phosphorous pentachloride.
  • the derivative ( v ) can then be turned into suitable 1-alkoxy-derivatives by reacting it with various alcohols Q-OH like methanol, ethanol or benzyl alcohol in the presence of a suitable base like sodium hydride and in a suitable solvent like dimethyl formamide, dimethyl acetamide or others.
  • ( v ) can be directly converted into the isoquinolinone derivative ( vii ) by reacting it with a reagent like ammonium acetate.
  • isoquinolines can be obtained by reacting suitable 3-formylated or acylated fluorobenzenes ( viii ), wherein z is for example H or alkyl like methyl or ethyl, with a reagent like triethyl phosphono acetate in the presence of a suitable base like sodium hydride to give the corresponding cinnamic acid ester, which subsequently is cleaved by action of a suitable base like potassium hydroxide, sodium hydroxide or lithium hydroxide in a suitable solvent to deliver acid ( ix ).
  • a suitable base like potassium hydroxide, sodium hydroxide or lithium hydroxide in a suitable solvent to deliver acid ( ix ).
  • ( ix ) can then be converted in the corresponding acid chloride by well known methods, which can be transferred into the acid azide by reaction with sodium azide in a suitable solvent like ether, chloroform or acetone in or without the presence of water.
  • the corresponding azide then can be converted into isoquinolinone (x) by reacting it in a suitable solvent like diphenylmethane or dipenylether at suitable temperature.
  • the products like ( xi ) obtained via this method can then, if a suitable amino functionality is present, be reacted with suitable aldehydes or ketones in the presence of a reducing agent like sodium triacetoxy borohydride, sodium borohydride or sodium cyanoborohydride in a suitable solvent and in the presence of a water withdrawing agent like molecular sieves or a suitable ortho ester.
  • a suitable amino functionality like sodium triacetoxy borohydride, sodium borohydride or sodium cyanoborohydride in a suitable solvent and in the presence of a water withdrawing agent like molecular sieves or a suitable ortho ester.
  • This amino group may have to be liberated in an initial step like for example acidic removal of Boc-groups.
  • Isoquinolone derivatives like ( xii ) can be obtained as free bases or as various salts like for example hydrochlorides, hydrobromides, phosphates, sulfates or fumarates.
  • the salts obtained can be converted into the corresponding free base by either subjecting them to ion exchange chromatography or for example by alkaline aqueous treatment and subsequent extraction with suitable organic solvents like for example methyl tert. butyl ether, chloroform, ethyl acetate or isopropanol / dichloromethane mixtures and subsequent evaporation to dryness.
  • the acid chloride was dissolved in 45 mL of acetone. At 0 °C 8.03 g of NaN 3 (123.5 mmol, 2 eq.) were added portionwise. Then 41 mL of water were added while the temperature was kept below 5 °C. The reaction was stirred for another 1.5 h. Then 55 mL of chloroform were added. The mixture was extracted with 80 mL of water followed by 40 mL of brine. After drying over Na 2 SO 4 and filtration 14 mL of diphenyl ether were added and most of the chloroform was removed in vacuo (without heating). A total removal of the chloroform should be avoided.
  • the crude intermediate was purified by preparative HPLC.
  • the protecting groups were removed by dissolving the protected intermediate in 2 mL of TFA and heating the reaction to 150 °C for 2 h in a microwave reactor.
  • the reaction mixture was quenched with methanol and evaporated to dryness.
  • the remaining residue was taken up in dichloromethane, extracted three times with 1 N HCl and the combined aqueous layer was extracted once with dichloromethane.
  • the combined aqueous layer was lyophilized, the remainder was taken up in water twice and lyophilized again to give the product as HCl salt.
  • the purity of the obtained product is sufficient, but eventually occurring impurities could be removed by silica gel chromatography or HPLC.
  • the used acrylic acids were either commercially available or synthesized from the corresponding aldehydes in similar fashion as described in the literature (see for instance: J. Med. Chem. 2005, 48, 71-90 ).
  • One example is described in the synthesis of 17 , step a.
  • Method A Stationary phase: Col YMC Jsphere 33 x 2 Gradient: ACN+0.05% TFA : H 2 O + 0.05% TFA 5:95(0 min) to 95:5(3.4 min) to 95:5(4.4 min) Flow 1 mL/min Method B: Gradient: ACN+0.05% TFA : H 2 O + 0.05% TFA 5:95(0 min) to 95:5(2.5 min) to 95:5(3.0 min) Flow 1 mL/min Method C: Stationary phase: Col YMC Jsphere ODS H80 20 x 2 Gradient: ACN : H 2 O + 0.05% TFA 4:96(0 min) to 95:5(2.0 min) to 95:5(2.4 min) Flow 1 mL/min Method D: Stationary phase: Col YMC Jsphere 33 x 2.1 Gradient: Grad ACN+0.08% FA:H 2 O+0.1%FA (Formic acid) 5:95 (0min) to 95:5 (2.5min) to 95:5 (3min)
  • IC 50 values were determined according to the following protocol:
  • the given activity is denoted as the negative decadal logarithm of the IC 50 (pIC 50 ) as follows: +: pIC50 ⁇ 3.0 ++: 3.0 ⁇ pIC 50 ⁇ 4.0 +++ 4.0 ⁇ pIC 50 ⁇ 5.0 ++++: 5.0 ⁇ pIC 50 ⁇ 6.0 +++++: 6.0 ⁇ pIC 50

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Reproductive Health (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
EP11176273.8A 2005-07-26 2006-07-20 Piperidinyl-substituted isoquinolone derivatives Active EP2385047B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP11176273.8A EP2385047B1 (en) 2005-07-26 2006-07-20 Piperidinyl-substituted isoquinolone derivatives

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05016154 2005-07-26
EP06776306.0A EP1910333B1 (en) 2005-07-26 2006-07-20 Piperidinyl-substituted isoquinolone derivatives as rho-kinase inhibitors
EP11176273.8A EP2385047B1 (en) 2005-07-26 2006-07-20 Piperidinyl-substituted isoquinolone derivatives

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP06776306.0 Division 2006-07-20

Publications (2)

Publication Number Publication Date
EP2385047A1 EP2385047A1 (en) 2011-11-09
EP2385047B1 true EP2385047B1 (en) 2013-05-29

Family

ID=34979095

Family Applications (2)

Application Number Title Priority Date Filing Date
EP06776306.0A Active EP1910333B1 (en) 2005-07-26 2006-07-20 Piperidinyl-substituted isoquinolone derivatives as rho-kinase inhibitors
EP11176273.8A Active EP2385047B1 (en) 2005-07-26 2006-07-20 Piperidinyl-substituted isoquinolone derivatives

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP06776306.0A Active EP1910333B1 (en) 2005-07-26 2006-07-20 Piperidinyl-substituted isoquinolone derivatives as rho-kinase inhibitors

Country Status (32)

Country Link
US (1) US8188117B2 (ru)
EP (2) EP1910333B1 (ru)
JP (1) JP5060478B2 (ru)
KR (1) KR101373535B1 (ru)
CN (1) CN101228149B (ru)
AR (1) AR054868A1 (ru)
AU (1) AU2006274245B2 (ru)
BR (1) BRPI0613861B8 (ru)
CA (1) CA2615577C (ru)
CR (1) CR9603A (ru)
DK (1) DK1910333T3 (ru)
DO (1) DOP2006000178A (ru)
EC (1) ECSP088135A (ru)
ES (1) ES2423006T3 (ru)
GT (1) GT200600328A (ru)
HK (1) HK1123035A1 (ru)
IL (1) IL188702A (ru)
MA (1) MA29636B1 (ru)
MX (1) MX2008001053A (ru)
MY (1) MY148479A (ru)
NI (1) NI200800025A (ru)
NO (1) NO341888B1 (ru)
NZ (1) NZ565668A (ru)
PE (1) PE20070217A1 (ru)
PT (1) PT1910333E (ru)
RU (1) RU2414467C2 (ru)
TN (1) TNSN08039A1 (ru)
TW (1) TWI383979B (ru)
UA (1) UA93882C2 (ru)
UY (1) UY29697A1 (ru)
WO (1) WO2007012421A1 (ru)
ZA (1) ZA200710951B (ru)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2611295C (en) 2005-06-28 2014-04-22 Sanofi-Aventis Isoquinoline derivatives as inhibitors of rho-kinase
AU2006274246B2 (en) 2005-07-26 2012-07-12 Sanofi-Aventis Cyclohexylamin isoquinolone derivatives as Rho-kinase inhibitors
TW200738682A (en) * 2005-12-08 2007-10-16 Organon Nv Isoquinoline derivatives
EP2066640B1 (en) * 2006-09-11 2011-09-07 N.V. Organon 2-(1-oxo-1h-isoquinolin-2-yl) acetamide derivatives
BRPI0720986A2 (pt) 2006-12-27 2014-03-11 Sanofi Aventis Derivados de isoquinolina e isoquinolinona substituídos
DE602007013295D1 (de) 2006-12-27 2011-04-28 Sanofi Aventis Substituierte isochinoline und ihre verwendung als rho-kinase-inhibitoren
RS51655B (en) 2006-12-27 2011-10-31 Sanofi-Aventis Isoquinoline derivatives and isoquinolinone derivatives substituted by cycloalkylamine
EP2125746B1 (en) 2006-12-27 2012-04-18 Sanofi Cycloalkylamine substituted isoquinoline derivatives
CA2673916C (en) 2006-12-27 2015-02-17 Sanofi-Aventis Substituted isoquinolone and isoquinolinone derivatives as inhibitors of rho-kinase
EP2125745B1 (en) 2006-12-27 2017-02-22 Sanofi Cycloalkylamine substituted isoquinolone derivatives
US9604931B2 (en) 2007-01-22 2017-03-28 Gtx, Inc. Nuclear receptor binding agents
EA019833B1 (ru) * 2007-01-22 2014-06-30 ДЖиТиЭкс, ИНК. Вещества, связывающие ядерные рецепторы
US9623021B2 (en) * 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
EP2240441B1 (en) * 2007-12-26 2015-06-03 Sanofi Process for the preparation of 6-substituted-1-(2h)-isoquinolinones
JP5714485B2 (ja) 2008-06-24 2015-05-07 サノフイ ６−置換イソキノリン類及びイソキノリノン類
JP5713893B2 (ja) 2008-06-24 2015-05-07 サノフイ Ｒｈｏ−キナーゼ阻害剤としての置換イソキノリン類及びイソキノリノン類
MX2010013867A (es) 2008-06-24 2011-02-24 Sanofi Aventis Derivados de isoquinolina e isoquinolinona bi- y policiclicos sustituidos.
US9865233B2 (en) 2008-12-30 2018-01-09 Intel Corporation Hybrid graphics display power management
MX2012004289A (es) * 2009-10-13 2012-06-12 Msd Oss Bv Derivados de azina condensada para el tratamiento de enfermedades relacionadas con el receptor de acetilcolina.
CN103957711A (zh) * 2011-07-04 2014-07-30 拜耳知识产权有限责任公司 取代的异喹啉酮、异喹啉二酮、异喹啉三酮和二氢异喹啉酮或其各自的盐作为活性剂对抗植物非生物胁迫的用途
CA2843777C (en) 2011-07-08 2018-11-06 Sanofi Polymorphs of 6-(piperidin-4-yloxy)-2h-isoquinolin-1-one hydrochloride
AU2012283335B2 (en) 2011-07-08 2016-09-01 Sanofi Substituted phenyl compounds
IN2014CN00817A (ru) * 2011-07-08 2015-04-03 Sanofi Sa
EP3141235A1 (en) 2012-12-06 2017-03-15 IP Gesellschaft für Management mbH N-(6-((2r,3s)-3,4-dihydroxybutan-2-yloxy)-2-(4-fluorobenzylthio)pyrimidin-4-yl)-3-methylazetidine-l -sulfonamide
RS60002B1 (sr) 2013-10-18 2020-04-30 Celgene Quanticel Research Inc Inhibitori bromodomena
ES2860695T3 (es) 2013-11-18 2021-10-05 Forma Therapeutics Inc Composiciones de tetrahidroquinolina como inhibidores de bromodominio BET
FR3017868A1 (fr) 2014-02-21 2015-08-28 Servier Lab Derives d'isoquinoleine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP3237414B1 (en) 2014-12-24 2019-05-08 Gilead Sciences, Inc. Fused pyrimidine compounds for the tratment of hiv
TWI770552B (zh) 2014-12-24 2022-07-11 美商基利科學股份有限公司 喹唑啉化合物
KR101960624B1 (ko) 2014-12-24 2019-03-20 길리애드 사이언시즈, 인코포레이티드 Hiv의 치료를 위한 이소퀴놀린 화합물
AR104259A1 (es) 2015-04-15 2017-07-05 Celgene Quanticel Res Inc Inhibidores de bromodominio
WO2017003723A1 (en) 2015-07-01 2017-01-05 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
US11096909B2 (en) * 2016-04-06 2021-08-24 University Of Oulu Compounds for use in the treatment of cancer
JP2019513804A (ja) 2016-04-18 2019-05-30 セルジーン クオンティセル リサーチ，インク． 治療用化合物
US10150754B2 (en) 2016-04-19 2018-12-11 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
CN106632258B (zh) * 2016-12-15 2019-04-02 三峡大学 四氢异喹啉-2-基芳氧基苯氧基烷基酮化合物及其应用
US11028068B2 (en) 2017-07-25 2021-06-08 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
US11738030B2 (en) 2021-10-30 2023-08-29 Aneuryst, Inc. Treatments for disturbed cerebral homeostasis
WO2024030854A1 (en) * 2022-08-01 2024-02-08 Valo Health, Inc. Process for preparing 6-substituted-1-(2h)-isoquinolinones and intermediate compound

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2485537B2 (fr) 1977-04-13 1986-05-16 Anvar Dipyrido(4,3-b)(3,4-f)indoles, procede d'obtention, application therapeutique et compositions pharmaceutiques les contenant
EP0541559A1 (en) 1990-07-31 1993-05-19 E.I. Du Pont De Nemours And Company Catalytic equilibration of selected halocarbons
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
GB9516709D0 (en) 1995-08-15 1995-10-18 Zeneca Ltd Medicament
ZA9610741B (en) 1995-12-22 1997-06-24 Warner Lambert Co 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists
EP0956865B2 (en) 1996-08-12 2010-08-18 Mitsubishi Tanabe Pharma Corporation MEDICINES COMPRISING Rho KINASE INHIBITOR
JPH1087629A (ja) 1996-09-18 1998-04-07 Fujisawa Pharmaceut Co Ltd 新規イソキノリン誘導体、およびその医薬用途
JP2001514259A (ja) 1997-08-29 2001-09-11 ゼネカ・リミテッド アミノメチルオキソオキサゾリジニルベンゼン誘導体
TW575567B (en) * 1998-10-23 2004-02-11 Akzo Nobel Nv Serine protease inhibitor
GB9912701D0 (en) 1999-06-01 1999-08-04 Smithkline Beecham Plc Novel compounds
US6541456B1 (en) 1999-12-01 2003-04-01 Isis Pharmaceuticals, Inc. Antimicrobial 2-deoxystreptamine compounds
AU779442B2 (en) 2000-01-20 2005-01-27 Eisai Co. Ltd. Novel piperidine compounds and drugs containing the same
US7217722B2 (en) 2000-02-01 2007-05-15 Kirin Beer Kabushiki Kaisha Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
AU2001239947A1 (en) 2000-02-29 2001-09-12 Curis, Inc. Methods and compositions for regulating adipocytes
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
AR033517A1 (es) 2000-04-08 2003-12-26 Astrazeneca Ab Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos
GB0013060D0 (en) 2000-05-31 2000-07-19 Astrazeneca Ab Chemical compounds
WO2002034712A1 (fr) 2000-10-27 2002-05-02 Takeda Chemical Industries, Ltd. Procede de preparation de composes aromatiques substitues et produits intermediaires associes
JP2004520347A (ja) 2001-01-15 2004-07-08 グラクソ　グループ　リミテッド Ｌｄｌ−受容体発現のインデューサーとしてのアリールピペリジンおよびピペラジン誘導体
SE0101038D0 (sv) 2001-03-23 2001-03-23 Astrazeneca Ab Novel compounds
JP2004534017A (ja) 2001-04-27 2004-11-11 バーテックス　ファーマシューティカルズ　インコーポレイテッド Ｂａｃｅのインヒビター
JPWO2002100833A1 (ja) * 2001-06-12 2004-09-24 住友製薬株式会社 Ｒｈｏキナーゼ阻害剤
GB0117899D0 (en) 2001-07-23 2001-09-12 Astrazeneca Ab Chemical compounds
WO2003024450A1 (en) 2001-09-20 2003-03-27 Eisai Co., Ltd. Methods for treating prion diseases
SE0104340D0 (sv) 2001-12-20 2001-12-20 Astrazeneca Ab New compounds
WO2004009555A1 (ja) * 2002-07-22 2004-01-29 Asahi Kasei Pharma Corporation ５−置換イソキノリン誘導体
AU2003264427A1 (en) 2002-09-12 2004-04-30 Kirin Beer Kabushiki Kaisha Isoquinoline derivatives having kinasae inhibitory activity and drugs containing the same
US20040266755A1 (en) 2003-05-29 2004-12-30 Schering Aktiengesellschaft Prodrugs of 1-(1-hydroxy-5-isoquinolinesulfonyl) homopiperazine
US20070021404A1 (en) 2003-06-24 2007-01-25 Dan Peters Novel aza-ring derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
CA2539479C (en) 2003-09-23 2010-07-06 Merck & Co., Inc. Isoquinoline potassium channel inhibitors
AU2004276236B2 (en) 2003-09-23 2008-01-24 Merck Sharp & Dohme Corp. Isoquinolinone potassium channel inhibitors
US20050067037A1 (en) 2003-09-30 2005-03-31 Conocophillips Company Collapse resistant composite riser
EP1671962A1 (en) 2003-10-10 2006-06-21 Ono Pharmaceutical Co., Ltd. Novel fused heterocyclic compound and use thereof
JP2007008816A (ja) * 2003-10-15 2007-01-18 Ube Ind Ltd 新規イソキノリン誘導体
US7449477B2 (en) 2003-11-25 2008-11-11 Eli Lilly And Company 7-phenyl-isoquinoline-5-sulfonylamino derivatives as inhibitors of akt (protein kinase B)
WO2005074535A2 (en) 2004-01-30 2005-08-18 Eisai Co., Ltd. Cholinesterase inhibitors for spinal cord disorders
WO2005087226A1 (en) 2004-03-05 2005-09-22 Eisai Co., Ltd. Cadasil treatment with cholinesterase inhibitors
SE0400850D0 (sv) 2004-03-30 2004-03-31 Astrazeneca Ab Novel Compounds
US7517991B2 (en) * 2004-10-12 2009-04-14 Bristol-Myers Squibb Company N-sulfonylpiperidine cannabinoid receptor 1 antagonists
AU2006274246B2 (en) 2005-07-26 2012-07-12 Sanofi-Aventis Cyclohexylamin isoquinolone derivatives as Rho-kinase inhibitors
TW200745101A (en) 2005-09-30 2007-12-16 Organon Nv 9-Azabicyclo[3.3.1]nonane derivatives
TW200738682A (en) * 2005-12-08 2007-10-16 Organon Nv Isoquinoline derivatives
US7618985B2 (en) 2005-12-08 2009-11-17 N.V. Organon Isoquinoline derivatives
US7893088B2 (en) 2006-08-18 2011-02-22 N.V. Organon 6-substituted isoquinoline derivatives
RS51655B (en) 2006-12-27 2011-10-31 Sanofi-Aventis Isoquinoline derivatives and isoquinolinone derivatives substituted by cycloalkylamine
DE602007013295D1 (de) 2006-12-27 2011-04-28 Sanofi Aventis Substituierte isochinoline und ihre verwendung als rho-kinase-inhibitoren

Also Published As

Publication number Publication date
NO341888B1 (no) 2018-02-12
WO2007012421A1 (en) 2007-02-01
KR20080028971A (ko) 2008-04-02
HK1123035A1 (en) 2009-06-05
AU2006274245B2 (en) 2011-11-24
EP1910333B1 (en) 2013-05-22
ZA200710951B (en) 2008-08-27
MX2008001053A (es) 2008-03-19
MA29636B1 (fr) 2008-07-01
IL188702A0 (en) 2008-08-07
JP2009502829A (ja) 2009-01-29
GT200600328A (es) 2007-02-22
KR101373535B1 (ko) 2014-03-12
JP5060478B2 (ja) 2012-10-31
DOP2006000178A (es) 2007-02-15
CA2615577A1 (en) 2007-02-01
ECSP088135A (es) 2008-02-20
CR9603A (es) 2008-03-06
RU2414467C2 (ru) 2011-03-20
CN101228149A (zh) 2008-07-23
BRPI0613861A2 (pt) 2011-02-15
BRPI0613861B1 (pt) 2019-12-10
AU2006274245A1 (en) 2007-02-01
RU2008106950A (ru) 2009-09-10
MY148479A (en) 2013-04-30
EP1910333A1 (en) 2008-04-16
NO20080963L (no) 2008-04-02
TWI383979B (zh) 2013-02-01
TW200918520A (en) 2009-05-01
DK1910333T3 (da) 2013-08-19
EP2385047A1 (en) 2011-11-09
CA2615577C (en) 2014-09-09
BRPI0613861B8 (pt) 2021-05-25
UY29697A1 (es) 2007-02-28
PT1910333E (pt) 2013-08-01
ES2423006T3 (es) 2013-09-17
US20090093518A1 (en) 2009-04-09
PE20070217A1 (es) 2007-03-19
US8188117B2 (en) 2012-05-29
CN101228149B (zh) 2013-01-02
UA93882C2 (ru) 2011-03-25
AR054868A1 (es) 2007-07-25
TNSN08039A1 (en) 2009-07-14
NI200800025A (es) 2009-03-03
NZ565668A (en) 2010-09-30
IL188702A (en) 2012-12-31

Similar Documents

Publication Publication Date Title
EP2385047B1 (en) Piperidinyl-substituted isoquinolone derivatives
EP1912949B1 (en) Cyclohexylamin isoquinolone derivatives as rho-kinase inhibitors
EP2102187B1 (en) Substituted isoquinoline and isoquinolinone derivatives as inhibitors of rho-kinase
EP2125745B1 (en) Cycloalkylamine substituted isoquinolone derivatives
EP2125744B1 (en) Cycloalkylamine substituted isoquinolone and isoquinolinone derivatives
EP2114920A1 (en) Substituted isoquinoline and isoquinolinone derivatives

Legal Events

Date Code Title Description
AC Divisional application: reference to earlier application

Ref document number: 1910333

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SANOFI

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SANOFI

17P Request for examination filed

Effective date: 20120509

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 401/12 20060101AFI20120726BHEP

Ipc: A61K 31/4725 20060101ALI20120726BHEP

Ipc: C07D 409/14 20060101ALI20120726BHEP

Ipc: A61P 9/12 20060101ALI20120726BHEP

Ipc: C07D 405/14 20060101ALI20120726BHEP

Ipc: C07D 401/14 20060101ALI20120726BHEP

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AC Divisional application: reference to earlier application

Ref document number: 1910333

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 614334

Country of ref document: AT

Kind code of ref document: T

Effective date: 20130615

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602006036620

Country of ref document: DE

Effective date: 20130725

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 614334

Country of ref document: AT

Kind code of ref document: T

Effective date: 20130529

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130929

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130529

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130529

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130529

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130529

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130529

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130909

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130830

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130930

REG Reference to a national code

Ref country code: NL

Ref legal event code: VDEP

Effective date: 20130529

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130829

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130529

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130529

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130529

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130529

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130529

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130529

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130529

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130529

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130529

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130529

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130529

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130731

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130731

26N No opposition filed

Effective date: 20140303

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602006036620

Country of ref document: DE

Effective date: 20140303

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130720

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130529

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130529

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20060720

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20130720

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 11

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 12

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 13

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230413

P02 Opt-out of the competence of the unified patent court (upc) changed

Effective date: 20230503

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20230720

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20230725

Year of fee payment: 18

Ref country code: DE

Payment date: 20230719

Year of fee payment: 18